Cusi, Kenneth

Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors

Francque, S., Szabo, G., Abdelmalek, M. F., Byrne, C. D., Cusi, K., Dufour, J.-F., Roden, M., Sacks, F., & Tacke, F. (2021) · Nature Reviews Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentPeroxisome Proliferator-Activated Receptors

Cited by 316

Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial

Bril, F., Biernacki, D. M., Kalavalapalli, S., Lomonaco, R., Subbarayan, S. K., Lai, J., Tio, F., Suman, A., Orsak, B. K., Hecht, J., et al. (2019) · Diabetes Care

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 312

Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis

Gastaldelli, A., Harrison, S. A., Belfort-Aguilar, R., Hardies, L. J., Balas, B., Schenker, S., & Cusi, K. (2009) · Hepatology

Liver Disease Diagnosis and TreatmentAdipokines, Inflammation, and Metabolic Diseases

Cited by 285

Lipid Infusion Decreases the Expression of Nuclear Encoded Mitochondrial Genes and Increases the Expression of Extracellular Matrix Genes in Human Skeletal Muscle

Richardson, D. K., Kashyap, S., Bajaj, M., Cusi, K., Mandarino, S. J., Finlayson, J., DeFronzo, R. A., Jenkinson, C. P., & Mandarino, L. J. (2005) · Journal of Biological Chemistry

Adipose Tissue and MetabolismMetabolism, Diabetes, and Cancer

Cited by 259

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase IIb study

Harrison, S. A., Alkhouri, N., Davison, B. A., Sanyal, A., Edwards, C., Colca, J. R., Lee, B. H., Loomba, R., Cusi, K., Kolterman, O., et al. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 211

Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes

Cusi, K., Bril, F., Barb, D., Polidori, D., Sha, S., Ghosh, A., Farrell, K., Sunny, N. E., Kalavalapalli, S., Pettus, J., et al. (2019) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementLiver Disease Diagnosis and Treatment

Cited by 204

Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes

Bril, F., Kalavalapalli, S., Clark, V. C., Lomonaco, R., Soldevila-Pico, C., Liu, I.-C., Orsak, B., Tio, F., & Cusi, K. (2018) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 199

Lipotoxicity in steatohepatitis occurs despite an increase in tricarboxylic acid cycle activity

Patterson, R. E., Kalavalapalli, S., Williams, C. M., Nautiyal, M., Mathew, J. T., Martinez, J., Reinhard, M. K., McDougall, D. J., Rocca, J. R., Yost, R. A., et al. (2016) · American Journal of Physiology-Endocrinology and Metabolism

Liver Disease Diagnosis and TreatmentDiet, Metabolism, and Disease

Cited by 161

Introduction and Methodology: Standards of Care in Diabetes—2025

American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Callaghan, B. C., et al. (2025) · Diabetes Care

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 155

Skeletal muscle insulin resistance in normoglycemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin-stimulated insulin receptor substrate-1 tyrosine phosphorylation

Pratipanawatr, W., Pratipanawatr, T., Cusi, K., Berria, R., Adams, J. M., Jenkinson, C. P., Maezono, K., DeFronzo, R. A., & Mandarino, L. J. (2001) · Diabetes

Metabolism, Diabetes, and CancerDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 118

Pharmacological management of nonalcoholic fatty liver disease

Barb, D., Portillo-Sanchez, P., & Cusi, K. (2016) · Metabolism

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 114

Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States

Golabi, P., Paik, J. M., Kumar, A., Al Shabeeb, R., Eberly, K. E., Cusi, K., GunduRao, N., & Younossi, Z. M. (2023) · Metabolism

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 113

Sustained Reduction in Plasma Free Fatty Acid Concentration Improves Insulin Action without Altering Plasma Adipocytokine Levels in Subjects with Strong Family History of Type 2 Diabetes

Bajaj, M., Suraamornkul, S., Kashyap, S., Cusi, K., Mandarino, L., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism

Adipokines, Inflammation, and Metabolic DiseasesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 109

Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes

Kashyap, S. R., Belfort, R., Berria, R., Suraamornkul, S., Pratipranawatr, T., Finlayson, J., Barrentine, A., Bajaj, M., Mandarino, L., DeFronzo, R., et al. (2004) · American Journal of Physiology-Endocrinology and Metabolism

Metabolism, Diabetes, and CancerDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 103

PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH

Gastaldelli, A., Sabatini, S., Carli, F., Gaggini, M., Bril, F., Belfort‐DeAguiar, R., Positano, V., Barb, D., Kadiyala, S., Harrison, S., et al. (2021) · Liver International

Liver Disease Diagnosis and TreatmentPeroxisome Proliferator-Activated Receptors

Cited by 101

A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis

Mak, L.-Y., Gane, E., Schwabe, C., Yoon, K. T., Heo, J., Scott, R., Lee, J.-H., Lee, J. I., Kweon, Y. O., Weltman, M., et al. (2023) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentRNA Interference and Gene Delivery

Cited by 98

Liver safety of statins in prediabetes or T2DM and nonalcoholic steatohepatitis: post hoc analysis of a randomized trial

Bril, F., Portillo Sanchez, P., Lomonaco, R., Orsak, B., Hecht, J., Tio, F., & Cusi, K. (2017) · The Journal of Clinical Endocrinology & Metabolism

Liver Disease Diagnosis and TreatmentDrug-Induced Hepatotoxicity and Protection

Cited by 97

Evaluation of PXL065–deuterium-stabilized (R)-pioglitazone in patients with NASH: a phase II randomized placebo-controlled trial (DESTINY-1)

Harrison, S. A., Thang, C., Bolze, S., Dewitt, S., Hallakou-Bozec, S., Dubourg, J., Bedossa, P., Cusi, K., Ratziu, V., Grouin, J.-M., et al. (2023) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentDrug-Induced Hepatotoxicity and Protection

Cited by 96

Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme

Cusi, K., Sattar, N., García‐Pérez, L. ‐., Pavo, I., Yu, M., Robertson, K. E., Karanikas, C. A., & Haupt, A. (2018) · Diabetic Medicine

Diabetes Treatment and ManagementLiver Disease Diagnosis and Treatment

Cited by 89

Selective Agonists of Thyroid Hormone Receptor Beta for the Treatment of NASH

Cusi, K. (2024) · New England Journal of Medicine

Liver Disease Diagnosis and TreatmentThyroid Disorders and Treatments

Cited by 78

Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles

Martínez‐Arranz, I., Bruzzone, C., Noureddin, M., Gil‐Redondo, R., Mincholé, I., Bizkarguenaga, M., Arretxe, E., Iruarrizaga‐Lejarreta, M., Fernández‐Ramos, D., Lopitz‐Otsoa, F., et al. (2022) · Hepatology

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 65

Adipose tissue insulin resistance predicts the severity of liver fibrosis in patients with type 2 diabetes and NAFLD

Kalavalapalli, S., Leiva, E. G., Lomonaco, R., Chi, X., Shrestha, S., Dillard, R., Budd, J., Romero, J. P., Li, C., Bril, F., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 64

Implementation of a liver health check in people with type 2 diabetes

Abeysekera, K. W. M., Valenti, L., Younossi, Z., Dillon, J. F., Allen, A. M., Noureddin, M., Rinella, M. E., Tacke, F., Francque, S., Ginès, P., et al. (2024) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 63

Normalization of Plasma Glucose Concentration by Insulin Therapy Improves Insulin-Stimulated Glycogen Synthesis in Type 2 Diabetes

Pratipanawatr, T., Cusi, K., Ngo, P., Pratipanawatr, W., Mandarino, L. J., & DeFronzo, R. A. (2002) · Diabetes

Diabetes, Cardiovascular Risks, and LipoproteinsMetabolism, Diabetes, and Cancer

Cited by 61